Literature DB >> 24510991

Expression of PDGFR-α, EGFR and c-MET in spinal chordoma: a series of 52 patients.

Reza Akhavan-Sigari1, Michael Robert Gaab, Veit Rohde, Mehdi Abili, Helmut Ostertag.   

Abstract

AIM: To investigate the expression of platelet-derived growth factor (PDGF) receptor-A (PDGFRα), epidermal growth factor receptor (EGFR) and c-Met in spinal chordoma. To the authors' knowledge, little is known regarding the prognostic significance of receptor tyrosine kinase in spinal chordoma.
MATERIALS AND METHODS: Using immunohistochemical techniques, the authors investigated PDGFR-α, EGFR and c-MET expression in 52 primary and 104 recurrent lesions, and compared these data with clinicopathological parameters.
RESULTS: PDGFR-α, EGFR and c-MET were found to be expressed in 75.0%, 83% and 77% of primary, and in 97.0% of recurrent lesions in all investigated receptor tyrosine kinases. Higher PDGFR-α and c-MET expression was found to be correlated with younger patient age. Lesions with a higher expression of PDGFR-α demonstrated significantly higher EGFR scores in both primary and recurrent lesions compared to those with lower PDGFR-α expression. In recurrent lesions, higher c-MET expression was found to be associated with significantly better prognosis than those with lower c-MET expression (p=0.033). Lesions with a higher level of PDGFR-α expression were found to have significantly poorer prognosis than those with lower PDGFR-α expression (p=0.024). Those patients with lower EGFR expression were found to have significantly better prognosis than those with higher EGFR expression (p=0.005).
CONCLUSION: In the current study, c-MET expression in patients with spinal chordoma was found to be correlated with a younger patient age and a favorable prognosis. Patients with a higher level of PDGFR-α and EGFR expression were found to have a significantly poorer prognosis than those with lower PDGFR-α and EGFR expression.

Entities:  

Keywords:  EGFR; PDGFR-α; c-MET; spinal chordoma

Mesh:

Substances:

Year:  2014        PMID: 24510991

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  22 in total

1.  [Novel molecular aspects of chordomas].

Authors:  S Scheil-Bertram
Journal:  Pathologe       Date:  2014-11       Impact factor: 1.011

Review 2.  Role of genetic and molecular profiling in sarcomas.

Authors:  Scott M Norberg; Sujana Movva
Journal:  Curr Treat Options Oncol       Date:  2015-05

3.  High expression of SPHK1 in sacral chordoma and association with patients' poor prognosis.

Authors:  Kai Zhang; Hao Chen; Guizhong Wu; Kangwu Chen; Huilin Yang
Journal:  Med Oncol       Date:  2014-09-27       Impact factor: 3.064

4.  Reduced expression of miRNA-1237-3p associated with poor survival of spinal chordoma patients.

Authors:  Ming-Xiang Zou; Wei Huang; Xiao-Bin Wang; Jing Li; Guo-Hua Lv; Bing Wang; You-Wen Deng
Journal:  Eur Spine J       Date:  2015-04-08       Impact factor: 3.134

Review 5.  Chordoma of the Head and Neck: A Review.

Authors:  Jason K Wasserman; Denis Gravel; Bibianna Purgina
Journal:  Head Neck Pathol       Date:  2017-10-04

6.  Upregulated human telomerase reverse transcriptase (hTERT) expression is associated with spinal chordoma growth, invasion and poor prognosis.

Authors:  Ming-Xiang Zou; Guo-Hua Lv; Jing Li; Xiao-Ling She; Yi Jiang
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

7.  Advancement of PI3 Kinase Inhibitor Combination Therapies for PI3K-Aberrant Chordoma.

Authors:  Molly E Heft Neal; Nicole L Michmerhuizen; Kevin J Kovatch; John Henry J Owen; Jingyi Zhai; Hui Jiang; Erin L McKean; Mark E P Prince; J Chad Brenner
Journal:  J Neurol Surg B Skull Base       Date:  2020-10-12

Review 8.  The molecular aspects of chordoma.

Authors:  Sukru Gulluoglu; Ozlem Turksoy; Aysegul Kuskucu; Ugur Ture; Omer Faruk Bayrak
Journal:  Neurosurg Rev       Date:  2015-09-12       Impact factor: 3.042

9.  AZD8055 enhances in vivo efficacy of afatinib in chordomas.

Authors:  Tianna Zhao; I-Mei Siu; Tara Williamson; Haoyu Zhang; Chenchen Ji; Peter C Burger; Nick Connis; Jacob Ruzevick; Menghang Xia; Lucia Cottone; Adrienne M Flanagan; Christine L Hann; Gary L Gallia
Journal:  J Pathol       Date:  2021-07-28       Impact factor: 9.883

10.  Sustained response of a clivus chordoma to erlotinib after imatinib failure.

Authors:  Aline Houessinon; Mathieu Boone; Jean-Marc Constans; Patrick Toussaint; Bruno Chauffert
Journal:  Case Rep Oncol       Date:  2015-01-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.